The commercial potential of monoclonal antibodies (mAbs) has been continuously increasing during the last years alongside with the number of approved mAb-based drugs and clinical trials. Despite their effectiveness and safety, the general access to this class of biopharmaceuticals is barred by high selling prices. Downstream processing is now considered the bottleneck in the manufacturing of mAbs. Therefore, the design of novel and economic operations and their implementation in the current technology platforms constitutes a pressing need. A recent review published by researchers from the Bioseparation Engineering Laboratory at BERG-iBB, provides an insight into the current state-of-the-art in mAbs purification, focusing on multimodal chromatography as one of the viable options to upgrade the established purification train. Multimodal chromatography has been receiving considerable attention over the last years, with about 152 publications published in ISI-index journals in the last decade (2004-2013). The number of publications per year has been steadily increasing, with a paper-boom starting in 2008.